用单克隆抗CD20抗体（利妥昔单抗）治疗难治性寻常型天疱疮。
Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab).
作者信息
Morrison Lynne H
机构信息
Department of Dermatology, Oregon Health Sciences University, Portland, Oregon 97239, USA.
出版信息
J Am Acad Dermatol. 2004 Nov;51(5):817-9. doi: 10.1016/j.jaad.2004.06.007.
PMID:15523367
Abstract
Three patients with refractory pemphigus vulgaris improved after rituximab, an anti-CD20 monoclonal antibody directed against B cells. Treatment was well tolerated immediately, but one patient developed fatal pneumocystis carinii pneumonia. Serious infections have occurred in several pemphigus patients treated with rituximab and immunosuppressive medications, warranting further evaluation of risk-benefit ratio.
摘要
三名寻常型天疱疮难治性患者在使用利妥昔单抗（一种针对B细胞的抗CD20单克隆抗体）后病情有所改善。治疗开始后耐受性良好，但有一名患者发生了致命的卡氏肺孢子虫肺炎。在数名接受利妥昔单抗和免疫抑制药物治疗的天疱疮患者中发生了严重感染，因此有必要进一步评估风险效益比。
Zotero 插件